Liver Cancer (Locally Advanced or Metastatic) clinical trials

Testing a new combination for advanced colorectal cancer

This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.

Study of new drug NDI-219216 for advanced solid tumors

This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.

Personalized chemo selection for advanced colorectal cancer

This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.

Tepotinib vs standard care for MET-mutated lung cancer

This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.

MRD-guided local therapy for oligometastatic breast cancer

This study is looking at a test called MRD (minimal residual disease) to see if it can guide decisions about local treatments (like surgery or radiation) for people with breast cancer that has spread to a few spots. It may help doctors know when to use these treatments and when to wait.

Stereotactic radiation vs standard radiation for limited cancer spread

This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.

K4Care test study for metastatic cancer patients

This study tests how well the K4Care blood test can monitor treatment in people with advanced solid tumors like lung, colorectal, breast, or stomach cancer that has spread. Researchers want to see if tracking tumor DNA in the blood helps guide therapy.

Exercise for quality of life in metastatic colorectal cancer

This trial tests whether a combination of resistance and aerobic exercise can improve quality of life for people starting their first round of chemotherapy for metastatic colorectal cancer. If you are newly diagnosed and not already exercising regularly, this study may help you feel better during treatment.

IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma

This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.

CAR-T cell therapy for CEA-positive advanced lung cancer

This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.

Heated chemo in abdomen plus IV chemo for pancreatic cancer

This trial tests a treatment that combines heating chemotherapy drugs and delivering them directly into the abdomen (HIPEC) with standard chemotherapy through a vein. It is for people whose pancreatic cancer has spread to the lining of the abdomen but not to other organs, and who have not had prior cancer treatment.

Vaccine plus immunotherapy for Merkel cell cancer

This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.

Comparing two treatments for advanced colorectal cancer with RAS mutations

This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.

Study of XB628 alone and with zanzalintinib for advanced solid tumors

This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.

Short radiation plus targeted drugs for advanced colon cancer

This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.

PET scan study for metastatic triple negative breast cancer

This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Study of tunlametinib for NRAS-mutant advanced thyroid cancer

This trial tests a targeted drug (tunlametinib) for advanced thyroid cancer that has a specific genetic change called NRAS mutation. It may help people whose cancer is not responding to standard treatments like radioactive iodine.

Study of a new drug for advanced bile duct cancer

This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.

A study of fruquintinib plus immunotherapy for advanced colorectal cancer

This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.

A new drug for advanced lung cancer that hasn't been treated yet

This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.

Glumetinib and Fruquintinib for advanced colorectal cancer

This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.

Testing JSB462 plus abiraterone for advanced prostate cancer

This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.

CAR-T cell therapy for advanced CEA-positive lung cancer

This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.